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ABSTRACT 
This thesis examines the abundance of total and activated mechanistic target of rapamycin 
(mTOR) pathway components in the developing and functional ruminant mammary gland.  
mTOR pathway activation is stimulated by a wide range of intra- and extracellular signals, 
such as amino acids (AA) and hormones, making the mTOR pathway a potential candidate 
for the development of intervention strategies designed to increase ruminant lactation 
potential. 
 
Tissues from two trials shown to improve lactation potential; dam-fetal nutrition and 
exogenous growth hormone (GH) administration during lactation, were used to measure 
changes in total and activated mTOR pathway protein abundance. Results show mammary 
glands of d 140 fetal lambs carried by maintenance fed dams and dairy cows administered 
exogenous GH, had increased abundance of total and activated mTOR and mitogen 
activated protein kinase (MAPK) pathway proteins. Increased abundance was associated 
with changes in biochemical indices. In the GH study MAPK pathway activation was 
stimulated by IGF-1 signaling whilst mTOR pathway activation was proposed to be 
mediated by AA signalling. Data from the GH study shows, L-arginine a known activator of 
the mTOR pathway, was the only AA reduced in both plasma and the lactating gland. 
Upstream factors were not identified for the phenotype observed in the dam-fetal nutrition 
study, but similar mechanisms were proposed. 
 
To elucidate the potential regulation of mTOR pathway activation by L-arginine and 
examine the effect on milk production, in vitro bovine cell culture models were evaluated. 
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Results show that none of the models evaluated produced a lactating phenotype – a pre-
requisite to accurately study the lactating gland in vitro. 
 
Finally, this thesis shows L-arginine administration from d 100 to d 140 of pregnancy, in 
twin bearing ewes had no effect on mTOR protein abundance or activation. However, 
administration from d 100 to parturition improved maternal gland health.  
 
In summary, this thesis associates improved lactation potential with increased total and 
activated mTOR pathway protein abundance, and the administration of L-arginine during 
late gestation with improved gland health. These findings provide fundamental knowledge 
that may lead to the development of novel technologies to increase ruminant gland 
performance and health. 
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GENERAL INTRODUCTION 
Ruminant milk production is a cornerstone of the New Zealand economy, earning in 2010 
close to $15.6-billion per annum in foreign currency. In addition, the dairy industry 
employs locally, almost seventy-five thousand people.  
 
The nutritional importance of milk has seen global demand rise, creating an opportunity 
for New Zealand dairy farmers to sell more milk, but simultaneously placing pressure on 
farmers to make constant productivity increases. Productivity increases that are being met 
through the application of novel environmental, genetic and nutritional intervention 
strategies. Environmental (soil maintenance, grazing intensity, water management, the 
introduction of new pasture species / cultivars) and genetic (breed selection, cross-
breeding) advances have traditionally focused on the whole animal, whilst nutritional 
strategies have focused on provision of an adequate nutrient supply to the mammary gland, 
in an effort to increase milk production.   
  
The ruminant mammary gland goes through very distinct developmental stages, fetal, pre-
pubertal, post-pubertal, pregnancy and lactation with each stage susceptible to nutrient 
manipulation that can negatively or positively influence lactation potential. Traditionally, 
nutrition studies in the dairy industry have focused on plane of nutrition (high, low, and 
stair-step), however, results have been inconsistent, with factors such as species, age of 
intervention and diet composition producing conflicting results. Current research shows 
supplementation with specific nutrients, such as amino acids (AA), at crucial stages of 
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development (pregnancy, gestation, lactation), may play an important role in helping the 
mammary gland reach full production potential.  
 
Amino acid uptake studies using arterio-venous differences across the lactating ruminant 
mammary gland show valine, leucine, arginine, lysine, and threonine are extracted in 
excess of milk protein outputs indicating possible roles in maintaining lactation. Arginine 
supplementation studies with late-pregnant Holstein cows increased milk yield, whilst the 
arginine-free diets retards mammary gland growth in rats. Glutamine is proposed to be 
limiting for milk protein synthesis due to three unique factors: uptake by the mammary 
gland is close to 99% of the arterial supply, high levels of glutamate are synthesised from 
glutamine and both glutamine, and glutamate are the most abundant AAs found in milk 
proteins. Arginine and glutamine belong to the arginine-family of AA (arginine, leucine and 
glutamine), long known to be important regulators of protein synthesis in multiple 
organisms. Studies show the arginine-family of AA enhance lactation potential, via possible 
direct or indirect stimulation of the nutrient-sensing mechanistic target of rapamycin 
(mTOR) pathway and reciprocal control of amino acid transporter (AAT) activity.  
 
The mTOR pathway integrates multiple environmental signals and metabolic pathways to 
regulate protein synthesis, cellular proliferation and development via phosphorylation of 
downstream targets involved in mRNA translation and nucleocytoplasmic export, cell size, 
rRNA and gene transcription. The mTOR pathway may be a rate-limiting step in the cellular 
development and function of the ruminant mammary gland, and the ability to enhance 
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mTOR signalling via AA may provide a novel intervention to enhance the production of 
milk in ruminants. 
 
The main objectives of this thesis were to understand the mTOR pathways role in the 
development and function of the ruminant mammary gland in response to external stimuli 
including nutrients and hormones, and to identify the potential role AAs play in stimulating 
mammary gland development and function through mTOR pathway signalling. The second 
objective was to develop a chronic in vitro model of bovine lactation to study the molecular 
mechanisms employed by AAs to regulate mTOR pathway signalling and the reciprocal 
control of AAT function. 
 
Knowledge gained from this research could potentially contribute to the development of 
future nutritional intervention strategies designed to enhance milk protein yield, with 
potential economic benefits to the dairy industry.
